# Empa/Lina FDC Food Effect Study (Japan)

> **NCT02815644** · PHASE1 · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 22 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** empagliflozin/linagliptin FDC

## Key facts

- **NCT ID:** NCT02815644
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-07-15
- **Primary completion:** 2016-10-05
- **Final completion:** 2016-10-05
- **Target enrollment:** 22 (ACTUAL)
- **Last updated:** 2018-08-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02815644

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02815644, "Empa/Lina FDC Food Effect Study (Japan)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02815644. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*